Research Article
Cost-Effectiveness of Oral Antidiabetic Drugs: A Prospective Multicenter Study of Real-World Patients
Table 4
Baseline characteristics (%).
| | Metformin | Xiaoke Pill | Other TCMs | Glimepiride | Acarbose | Xiaoke Pill + others | Glibenclamide | Others | Total | ANOVA: value |
| 60 > age ≥ 50 | 25 | 31 | 26 | 20 | 15 | 25 | 17 | 25 | 25 | 0.06 | 70 >age ≥ 60 | 31 | 27 | 35 | 40 | 37 | 26 | 33 | 35 | 33 | 0.05 | Age ≥ 70 | 22 | 20 | 31 | 30 | 34 | 24 | 8 | 28 | 27 | 0.03 | Male | 46 | 41 | 45 | 45 | 46 | 41 | 50 | 45 | 44 | 0.88 | Lower secondary education | 40 | 41 | 39 | 34 | 38 | 34 | 42 | 34 | 36 | 0.44 | Upper secondary education | 24 | 21 | 28 | 15 | 26 | 20 | 33 | 25 | 24 | 0.12 | Tertiary education | 14 | 16 | 7 | 9 | 17 | 16 | 0 | 13 | 13 | 0.07 | Shenyang | 33 | 42 | 74 | 17 | 18 | 10 | 33 | 12 | 23 | 0.00 | Chengdu | 24 | 27 | 6 | 16 | 26 | 33 | 25 | 19 | 21 | 0.00 | Nanjing | 16 | 8 | 4 | 53 | 12 | 5 | 42 | 24 | 19 | 0.00 | Guangzhou | 11 | 14 | 7 | 10 | 15 | 39 | 0 | 24 | 20 | 0.00 | 2000 > income ≥ 1000 | 49 | 37 | 53 | 31 | 31 | 28 | 58 | 38 | 38 | 0.00 | Income ≥ 2000 | 31 | 33 | 20 | 23 | 51 | 46 | 0 | 39 | 36 | 0.00 | UEBMI | 65 | 64 | 69 | 41 | 72 | 63 | 58 | 65 | 64 | 0.00 | NRCM | 5 | 5 | 3 | 30 | 2 | 9 | 8 | 11 | 10 | 0.00 | Govern. insur. | 4 | 3 | 2 | 5 | 9 | 6 | 0 | 6 | 5 | 0.24 | Currently smoking | 25 | 21 | 27 | 16 | 19 | 18 | 33 | 19 | 20 | 0.18 | Currently drinking | 29 | 27 | 18 | 27 | 28 | 20 | 25 | 25 | 25 | 0.25 | Any physical exercise | 81 | 84 | 79 | 68 | 80 | 81 | 58 | 79 | 79 | 0.02 | Diet control | 89 | 85 | 84 | 88 | 93 | 92 | 92 | 91 | 90 | 0.03 | 10 > duration ≥ 5 | 19 | 20 | 24 | 35 | 19 | 29 | 42 | 28 | 26 | 0.00 | Duration ≥ 10 | 17 | 17 | 34 | 16 | 15 | 24 | 17 | 29 | 24 | 0.00 | Heart disease | 18 | 21 | 40 | 20 | 25 | 16 | 17 | 19 | 21 | 0.00 | Hypertension | 53 | 35 | 55 | 48 | 64 | 46 | 8 | 51 | 49 | 0.00 | Dyslipidemia | 27 | 16 | 26 | 20 | 26 | 11 | 8 | 20 | 20 | 0.00 | Stroke | 11 | 5 | 16 | 13 | 10 | 5 | 0 | 7 | 8 | 0.00 | Baseline BMI | 67 | 54 | 59 | 70 | 55 | 47 | 42 | 58 | 58 | 0.00 | Baseline HbA1c | 42 | 53 | 29 | 37 | 51 | 46 | 33 | 33 | 39 | 0.00 | Baseline FBS | 47 | 61 | 31 | 42 | 59 | 54 | 33 | 39 | 45 | 0.00 | Baseline hypoglycemia | 12 | 9 | 9 | 10 | 8 | 9 | 8 | 13 | 11 | 0.35 | Baseline SBP | 44 | 33 | 44 | 54 | 39 | 38 | 50 | 39 | 40 | 0.01 | Baseline DBP | 33 | 27 | 28 | 37 | 18 | 27 | 42 | 23 | 26 | 0.00 | Baseline TC | 42 | 41 | 52 | 22 | 28 | 40 | 33 | 40 | 39 | 0.00 | Baseline TG | 51 | 39 | 46 | 39 | 33 | 38 | 50 | 41 | 41 | 0.04 | Baseline HRQoL | 47 | 52 | 46 | 45 | 55 | 53 | 50 | 46 | 48 | 0.46 |
| Observations | 203 | 233 | 137 | 128 | 110 | 177 | 12 | 903 | 1903 | 1903 |
|
|
Note: the last column includes significant levels derived from ANOVA tests regarding variable difference between different therapies.
|